Beeline’s oral lupus drug afimetoran delivers positive Phase 2 results

Beeline Medicines announced positive topline results on September 9, 2026, from a global Phase 2 trial of afimetoran in systemic lupus erythematosus (SLE).

The study met its primary endpoint:
all three afimetoran dose groups produced significantly higher SRI-4 response rates at Week 48 than placebo, with p-values below 0.001.

Secondary measures—including disease activity, skin and joint symptoms, corticosteroid reduction, physician assessments, and quality of life—also reportedly improved in line with the primary result.

Afimetoran was generally well tolerated, with no new safety signals and a profile consistent with earlier Phase 1 experience.

Beeline plans to advance afimetoran into pivotal studies for both systemic and cutaneous lupus. Detailed trial results are expected at a future medical congress.

The randomized, double-blind, placebo-controlled trial enrolled 248 adults with active SLE and evaluated the once-daily oral TLR7/8 inhibitor afimetoran.